Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.

Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. N Engl J Med (2016) 3.40

Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial. Circulation (2015) 3.26

Saphenous vein graft failure after coronary artery bypass surgery: insights from PREVENT IV. Circulation (2014) 3.04

Association between endoscopic vs open vein-graft harvesting and mortality, wound complications, and cardiovascular events in patients undergoing CABG surgery. JAMA (2012) 3.00

Endoscopic venous harvesting by inexperienced operators compromises venous graft remodeling. Ann Thorac Surg (2011) 2.09

Impact of extracardiac vascular disease on vein graft failure and outcomes after coronary artery bypass surgery. Ann Thorac Surg (2013) 1.99

Disparity in outcomes of surgical revascularization for limb salvage: race and gender are synergistic determinants of vein graft failure and limb loss. Circulation (2008) 1.80

Vein graft preservation solutions, patency, and outcomes after coronary artery bypass graft surgery: follow-up from the PREVENT IV randomized clinical trial. JAMA Surg (2014) 1.61

Effects of aspirin responsiveness and platelet reactivity on early vein graft thrombosis after coronary artery bypass graft surgery. J Am Coll Cardiol (2011) 1.59

Intimal thickness associated with endothelial dysfunction in human vein grafts. J Surg Res (2012) 1.58

Retracted Rapamycin-loaded nanoparticles for inhibition of neointimal hyperplasia in experimental vein grafts. J Cardiothorac Surg (2011) 1.42

Mechanisms of vein graft adaptation to the arterial circulation: insights into the neointimal algorithm and management strategies. Circ J (2010) 1.39

Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study. BMJ (2013) 1.22

Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results. Am Heart J (2012) 1.22

Coronary vein graft disease: pathogenesis and prevention. Can J Cardiol (2009) 1.20

Neointimal hyperplasia associated with synthetic hemodialysis grafts. Kidney Int (2008) 1.18

Detrimental effects of mechanical stretch on smooth muscle function in saphenous veins. J Vasc Surg (2010) 1.14

A single direct injection into the left ventricular wall of an adeno-associated virus 9 (AAV9) vector expressing extracellular superoxide dismutase from the cardiac troponin-T promoter protects mice against myocardial infarction. J Gene Med (2011) 1.12

Gene therapy and vein graft patency in coronary artery bypass graft surgery. JAMA (2005) 1.09

Effect of anti-platelet factor-4/heparin antibody induction on early saphenous vein graft occlusion after coronary artery bypass surgery. J Thromb Haemost (2009) 1.09

Eph-B4 prevents venous adaptive remodeling in the adult arterial environment. J Exp Med (2011) 1.08

Strategies to reduce intraluminal clot formation in endoscopically harvested saphenous veins. J Thorac Cardiovasc Surg (2007) 1.06

Pressure control during preparation of saphenous veins. JAMA Surg (2014) 1.05

Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgery. Circulation (2012) 1.05

Surgical skin markers impair human saphenous vein graft smooth muscle and endothelial function. Am Surg (2011) 1.03

Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia. Proc Natl Acad Sci U S A (2007) 1.01

Surgical vein graft preparation promotes cellular dysfunction, oxidative stress, and intimal hyperplasia in human saphenous vein. J Vasc Surg (2013) 1.00

Aptamers and aptamer targeted delivery. RNA Biol (2009) 1.00

Human umbilical cord blood-derived endothelial cells reendothelialize vein grafts and prevent thrombosis. Arterioscler Thromb Vasc Biol (2010) 0.97

Rationale and practical techniques for mouse models of early vein graft adaptations. J Vasc Surg (2010) 0.96

Cardiovascular Gene Therapy: Past, Present, and Future. Mol Ther (2017) 0.95

miRNA-21 is dysregulated in response to vein grafting in multiple models and genetic ablation in mice attenuates neointima formation. Eur Heart J (2013) 0.95

Mouse vein graft hemodynamic manipulations to enhance experimental utility. Am J Pathol (2011) 0.92

Inhibition of Mitogen Activated Protein Kinase Activated Protein Kinase II with MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. Vascul Pharmacol (2011) 0.92

Vein graft failure. J Vasc Surg (2013) 0.88

Proliferative capacity of vein graft smooth muscle cells and fibroblasts in vitro correlates with graft stenosis. J Vasc Surg (2009) 0.88

Pre-operative homocysteine levels and morbidity and mortality following cardiac surgery. Eur Heart J (2009) 0.88

Cytokines and the early vein graft: strategies to enhance durability. J Vasc Surg (2007) 0.88

Monocyte chemoattractant protein-1/CCR2 axis promotes vein graft neointimal hyperplasia through its signaling in graft-extrinsic cell populations. Arterioscler Thromb Vasc Biol (2012) 0.88

A single nucleotide polymorphism in the p27(Kip1) gene is associated with primary patency of lower extremity vein bypass grafts. J Vasc Surg (2013) 0.87

Relative importance of patient, procedural and anatomic risk factors for early vein graft thrombosis after coronary artery bypass graft surgery. J Cardiovasc Surg (Torino) (2011) 0.87

Current state of surgical myocardial revascularization. Circ J (2010) 0.87

Therapeutic strategies to combat neointimal hyperplasia in vascular grafts. Expert Rev Cardiovasc Ther (2012) 0.87

Rule-based model of vein graft remodeling. PLoS One (2013) 0.86

Surgery: Open or endoscopic vein graft harvesting-this is the question! Nat Rev Cardiol (2009) 0.85

Hybrid Coronary Revascularization for the Treatment of Multivessel Coronary Artery Disease: A Multicenter Observational Study. J Am Coll Cardiol (2016) 0.85

Endoscopic harvesting device type and outcomes in patients undergoing coronary artery bypass surgery. Ann Surg (2014) 0.85

ETS1 regulates the expression of ATXN2. Hum Mol Genet (2012) 0.84

Expression of apolipoprotein A-I in rabbit carotid endothelium protects against atherosclerosis. Mol Ther (2011) 0.83

Inhibition of adhesion molecule expression on human venous endothelial cells by non-viral siRNA transfection. J Cell Mol Med (2007) 0.83

Status quo of hybrid coronary revascularization for multi-vessel coronary artery disease. Ann Thorac Surg (2013) 0.82

Brilliant blue FCF is a nontoxic dye for saphenous vein graft marking that abrogates response to injury. J Vasc Surg (2015) 0.82

High-frequency epicardial ultrasound: review of a multipurpose intraoperative tool for coronary surgery. Surg Endosc (2008) 0.82

Preventing intimal thickening of vein grafts in vein artery bypass using STAT-3 siRNA. J Transl Med (2012) 0.81

Development of viral vectors for use in cardiovascular gene therapy. Viruses (2010) 0.81

Advances in surgical treatment of acute and chronic coronary artery disease. Tex Heart Inst J (2010) 0.80

Ephrin type-B receptor 4 activation reduces neointimal hyperplasia in human saphenous vein in vitro. J Vasc Surg (2014) 0.80

Hybrid coronary revascularization using limited incisional full sternotomy coronary artery bypass surgery in multivessel disease: early results. Korean J Thorac Cardiovasc Surg (2014) 0.79

Improving long term outcome for diabetic patients undergoing surgical revascularization by use of the radial artery conduit: a propensity matched study. J Cardiothorac Surg (2013) 0.79

MK2 inhibitory peptide delivered in nanopolyplexes prevents vascular graft intimal hyperplasia. Sci Transl Med (2015) 0.79

Saphenous vein graft failure and clinical outcomes: toward a surrogate end point in patients following coronary artery bypass surgery? Am Heart J (2013) 0.79

Expandable external support device to improve Saphenous Vein Graft Patency after CABG. J Cardiothorac Surg (2013) 0.79

Pathogenesis and local drug delivery for prevention of vascular access stenosis. J Ren Nutr (2008) 0.78

Endothelial cells are susceptible to rapid siRNA transfection and gene silencing ex vivo. J Vasc Surg (2010) 0.78

Contrasting roles of E2F2 and E2F3 in cardiac neovascularization. PLoS One (2013) 0.78

Gene therapy for the prevention of vein graft disease. Transl Res (2012) 0.78

Combining PCI and CABG: the role of hybrid revascularization. Curr Cardiol Rep (2013) 0.78

Role of the renin-angiotensin system in the pathogenesis of intimal hyperplasia: therapeutic potential for prevention of vein graft failure? Ann Vasc Surg (2012) 0.78

Endosomolytic Nano-Polyplex Platform Technology for Cytosolic Peptide Delivery To Inhibit Pathological Vasoconstriction. ACS Nano (2015) 0.78

Inhibition of transforming growth factor-β restores endothelial thromboresistance in vein grafts. J Vasc Surg (2011) 0.78

Efficacy and safety of edifoligide. JAMA (2006) 0.77

Vein graft neointimal hyperplasia is exacerbated by CXCR4 signaling in vein graft-extrinsic cells. J Vasc Surg (2012) 0.77

Nucleic acid drugs for prevention of cardiac rejection. J Biomed Biotechnol (2009) 0.77

Genome-wide association study of perioperative myocardial infarction after coronary artery bypass surgery. BMJ Open (2015) 0.77

Arterial shear stress reduces eph-b4 expression in adult human veins. Yale J Biol Med (2014) 0.77

Immobilization of iron oxide magnetic nanoparticles for enhancement of vessel wall magnetic resonance imaging--an ex vivo feasibility study. Bioconjug Chem (2010) 0.77

Periadventitial drug delivery for the prevention of intimal hyperplasia following open surgery. J Control Release (2016) 0.77

Contrasting roles of E2F2 and E2F3 in endothelial cell growth and ischemic angiogenesis. J Mol Cell Cardiol (2013) 0.77

Diet-induced obesity drives negative mouse vein graft wall remodeling. J Vasc Surg (2013) 0.77

Modulating vascular intimal hyperplasia using HSV-1 mutant requires activated MEK. Gene Ther (2012) 0.76

Lack of interleukin-1 signaling results in perturbed early vein graft wall adaptations. Surgery (2012) 0.76

Efficient gene transfer and durable transgene expression in grafted rabbit veins. Hum Gene Ther (2015) 0.76

Use of Brilliant Blue FCF during vein graft preparation inhibits intimal hyperplasia. J Vasc Surg (2016) 0.76

The source of neointimal cells in vein grafts: does the origin matter? Am J Pathol (2008) 0.76

Coronary artery bypass graft surgery: the past, present, and future of myocardial revascularisation. Surg Res Pract (2014) 0.75

Biomaterial-Based Approaches to Address Vein Graft and Hemodialysis Access Failures. Macromol Rapid Commun (2016) 0.75

Gene Therapy in Cardiac Surgery: Clinical Trials, Challenges, and Perspectives. Ann Thorac Surg (2016) 0.75

A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial. Can J Cardiol (2009) 0.75

Potential Effect of L-Carnitine on the Prevention of Myocardial Injury after Coronary Artery Bypass Graft Surgery. J Tehran Heart Cent (2015) 0.75

The role of preexisting pathology in the development of neointimal hyperplasia in coronary artery bypass grafts. J Surg Res (2007) 0.75

Antianginal Efficacy of Ivabradine in Patients With History of Coronary Revascularization. Angiology (2016) 0.75

Efficacy and safety of edifoligide. JAMA (2006) 0.75

Physiology of in-situ arterial revascularization in coronary artery bypass grafting: Preoperative, intraoperative and postoperative factors and influences. World J Cardiol (2016) 0.75

Revascularization in multivessel CAD: a functional approach. Nat Rev Cardiol (2012) 0.75

Covalent modification of pericardial patches for sustained rapamycin delivery inhibits venous neointimal hyperplasia. Sci Rep (2017) 0.75

Traditional graft preparation decreases physiologic responses, diminishes viscoelasticity, and reduces cellular viability of the conduit: A porcine saphenous vein model. Vasc Med (2016) 0.75

Collagen External Scaffolds Mitigate Intimal Hyperplasia and Improve Remodeling of Vein Grafts in a Rabbit Arteriovenous Graft Model. Biomed Res Int (2017) 0.75

Calcification of Human Saphenous Vein Associated with Endothelial Dysfunction: A Pilot Histopathophysiological and Demographical Study. Front Surg (2017) 0.75

Efficacy and safety of edifoligide. JAMA (2006) 0.75

Intraluminal Drug Delivery to the Mouse Arteriovenous Fistula Endothelium. J Vis Exp (2016) 0.75

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99

Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation (2009) 27.89

Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03

Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med (2009) 17.17

Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med (2011) 15.70

Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2008) 15.35

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med (2015) 13.90

Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA (2009) 13.69

Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2009) 12.34

Universal definition of myocardial infarction. Circulation (2007) 11.69

Ethical and scientific implications of the globalization of clinical research. N Engl J Med (2009) 11.42

Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med (2013) 11.14

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57

ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol (2007) 10.19

The ClinicalTrials.gov results database--update and key issues. N Engl J Med (2011) 9.83

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med (2015) 9.70

Low diagnostic yield of elective coronary angiography. N Engl J Med (2010) 9.38

Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation (2010) 9.18

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13

2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation (2010) 9.07

Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA (2002) 8.28

Application of new cholesterol guidelines to a population-based sample. N Engl J Med (2014) 8.22

Door-to-balloon time and mortality among patients undergoing primary PCI. N Engl J Med (2013) 8.08

Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA (2006) 7.81

Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA (2009) 7.78

ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology. J Am Coll Cardiol (2006) 7.77

A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09

Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA (2010) 6.91

Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86

ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation (2007) 6.78

2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2009) 6.61

Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N Engl J Med (2013) 6.21

Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA (2005) 6.10

Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA (2006) 5.78

ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation (2009) 5.49

Comparative effectiveness of revascularization strategies. N Engl J Med (2012) 5.49

Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 5.46

Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. N Engl J Med (2009) 5.19

Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA (2004) 5.11

Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med (2006) 5.07

Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA (2013) 5.05

Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 5.04

2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology,American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons,and Society for Vascular Medicine. J Am Coll Cardiol (2010) 4.90

Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA (2007) 4.89

Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81

Surgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med (2015) 4.77

2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol (2012) 4.77

2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation (2009) 4.75

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA (2003) 4.74

Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med (2003) 4.72

ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography). Circulation (2007) 4.66

AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation (2011) 4.65

ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol (2002) 4.64

2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2014) 4.57

What clinicians should know about the QT interval. JAMA (2003) 4.45

Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med (2006) 4.44

A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. N Engl J Med (2002) 4.42

The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1--coronary artery bypass grafting surgery. Ann Thorac Surg (2009) 4.39

Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med (2010) 4.38

Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet (2013) 4.34

Compliance with results reporting at ClinicalTrials.gov. N Engl J Med (2015) 4.17

Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med (2013) 4.16

Variation in use of blood transfusion in coronary artery bypass graft surgery. JAMA (2010) 4.13

Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol (2006) 4.11

An empirically based tool for analyzing mortality associated with congenital heart surgery. J Thorac Cardiovasc Surg (2009) 4.10

Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation (2012) 4.10

Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA (2011) 4.09

Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA (2008) 4.06

Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. JAMA (2011) 3.97

Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation (2006) 3.96

Validation of European System for Cardiac Operative Risk Evaluation (EuroSCORE) in North American cardiac surgery. Eur J Cardiothorac Surg (2002) 3.86

Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med (2005) 3.83

ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation (2002) 3.80

Pay for performance, quality of care, and outcomes in acute myocardial infarction. JAMA (2007) 3.79

Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med (2002) 3.77

ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol (2003) 3.76

Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res (2011) 3.72

Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA (2005) 3.72

Conversion of cardiovascular conference abstracts to publications. Circulation (2012) 3.71

Procedural volume as a marker of quality for CABG surgery. JAMA (2004) 3.70

Association between stroke center hospitalization for acute ischemic stroke and mortality. JAMA (2011) 3.68

Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. JAMA (2012) 3.66